IN BRIEF: Aptamer signs Optimer contract with US biotech Alphazyme

Aptamer Group PLC - York, England-based synthetic binders developer - Strikes licensing agreement with Alphazyme Inc. This grants Jupiter, Florida-based biotechnology company Alphazyme a non-exclusive licence for use of an enzyme-modulating Optimer in hot-start polymerase chain reaction and next-generation sequencing applications within Alphazyme's own products and services. Optimer binders are advanced molecules that work like antibodies by attaching to specific targets in the body.

The agreement provides worldwide rights to Alphazyme and includes royalty payments on sales of products, milestone payments, and a supply agreement for the manufacturing of the Optimer. Aptamer will manufacture the Optimer for Alphazyme, providing quality assurance and supply chain security whilst generating additional manufacturing revenue.

Current stock price: 0.86 pence, up 7.2% in London on Tuesday

12-month change: more than doubled from 0.37p

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Aptamer Group